Biphasic human insulin 30 thrice daily, is it reasonable?

OBJECTIVE: To evaluate the efficacy and safety of thrice daily Biphasic Human Insulin 30 (BHI 30) versus the traditional twice-daily regimen in type 2 diabetes mellitus (T2DM) patients. It’s a cross over single clinical study. Twenty-two diabetic patients who were already using BHI 30 in twice or th...

Descripción completa

Detalles Bibliográficos
Autores principales: Saadeh, Nesreen A., Al-Azzeh, Ola Y., Khader, Yousef S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Note
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7247174/
https://www.ncbi.nlm.nih.gov/pubmed/32448382
http://dx.doi.org/10.1186/s13104-020-05090-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7247174/
https://www.ncbi.nlm.nih.gov/pubmed/32448382
http://dx.doi.org/10.1186/s13104-020-05090-6

Ejemplares similares